Comment on "Inflammasome Activation of IL-18 Results in Endothelial Progenitor Cell Dysfunction in Systemic Lupus Erythematosus" R ecently, Kahlenberg et al. (1) found that inhibition of caspase-l disrupted IFN-a-mediated endothelial progenitor cell (EPC)/circulating angiogenic cell (CAC) dysfunction in murine and human systems. It lends more information on the role of IFN-a, which might promote atherosclerosis in systemic lupus erythematosus (SLE).
To date, the etiology and pathogenic mechanisms of SLE have not been clearly elucidated. It is well known that SLE was characterized by increased vascular risk due to premature atherosclerosis. Denny et al. (2) discovered that patients displayed aberrant phenotype and function of EPCs/CACs, characterized by significantly decreased circulating EPCs and impairments in the capacity of EPCs/CACs to differentiate into mature endothelial cells, and produced adequate levels of the proangiogenic molecule vascular endothelial growth factor (VEGF). These abnormalities are triggered by IFN-a, which induces EPC and CAC apoptosis and skews myeloid cells toward nonangiogenic phenotypes. Importantly, neutralization of IFN pathways restores a normal EPC/CAC phenotype in lupus. Furthermore, Thacker et al. (3) showed that NZB/W mice manifested reduced numbers and increased apoptosis and impaired function of EPCs. This abnormality was related to significant decreases in endothelium-dependent vasomotor responses and with upregulated type I IFN signature in EPC compartments. On the contrary, B6/lpr mice reflected improvement in endothelium-dependent and endothelium-independent responses, no abnormalities in EPC phenotype or function, and downregulation of type I IFN signatures in EPC compartments. In addition, Thacker et al. (4) demonstrated that IFN-a promoted an antiangiogenic signature in SLE and control EPCs/CACs, characterized by transcriptional repression of IL-la/b, IL-1R1, and VEGF-A and augmentation of the IL-1R antagonist (IL-1RN) and the decoy receptor IL1-R2. The study found a novel putative pathway by which IFN-a may interfere with vascular repair in SLE through repression of IL-1-dependent pathways.
Collectively, these findings suggest that IFN-a might play an important role in vascular damage and, potentially, atherosclerosis development in SLE. However, more studies are still needed to clarify the role of IFN-a, based on the association with EPCs/CACs in SLE, especially with atherosclerosis. W e thank Drs. Duan et al. for their comments and for summarizing the observations of several of our recent publications that focus on the putative roles of type I IFNs in the development of premature cardiovascular damage in systemic lupus erythematosus. We agree with them that additional studies are needed to further clarify the role of type I IFNs in the development of premature atherosclerosis in lupus, other autoimmune diseases, and in the general population.
Very recently, we have demonstrated that type I IFNs modulate vascular repair, vasomotor tone, thrombosis, and plaque progression in murine models of lupus and atherosclerosis; these observations provide additional in vivo evidence for a prominent role of these cytokines in vessel damage (1) . There is also evidence that other type I IFNs besides IFN-a are proatherogenic in rodents (2) . All these observations support the notion that these cytokines should be evaluated as putative biomarkers of vascular risk in various autoimmune diseases associated with endothelial damage, as well as in the general population. Indeed, the pathways leading to atherosclerosis and cardiovascular events are likely heterogeneous with regard to initial inflammatory events that promote endothelial damage and promote plaque progression. We hope that advancing the understanding of the mechanisms that lead to the striking increases in Helios expression is a marker of T cell activation and proliferation. PLoS ONE 6: e24226. W e recently reported in the The Journal of Immunology that Helios is expressed in peripherally induced T regulatory cells (Treg), precluding the use of this transcription factor as a marker of thymically-derived natural Treg (1). We noted differences in the optimal conditions for Helios and Foxp3 induction in vitro, and in the kinetics of their expression in vivo. Following a single dose of i.v. peptide, the robust Helios expression described in our study was more rapid than induction of Foxp3, but began to decrease 2-3 wk after stimulation without a second administration of Ag.
While Helios does not discriminate thymic Treg from those that develop in the periphery, we agree that Treg expression of Helios remains of significant interest and potential therapeutic importance. The expression of effector cytokines by Heliosnegative Treg from human peripheral blood (2) is of partic- mice were in a C57BL/6 (B6) background, but their cholesterol levels (∼ 280mg/dl) were abnormally high compared with the 10xB6J-SR-BI 2/2 mice in our hands. According to Dr. Bocharov (personal communication), the mice were in 5xB6N, rather than 103 backcrossed. It is inappropriate to use B6N mice as controls, given the profound survival advantage of mice in a mixed background. 2) Problematic data. It is impossible to get 55% survival for CD36
2/2 (n 5 17), 17% for WT (n 5 17) (Fig. 6A in Ref. 1 ), 48% for SR-BI 2/2 1 S (n 5 9), and 5% for WT1S (n 5 10) (Fig. 6B in Ref. 1) given the sample sizes. For example, the 5% survival would imply that 0.5 mice out of 10 survived. 3) Pretreatment with steroids 24 h before cecal ligation and puncture (CLP). This approach does not seem justified, since SR-BI 2/2 mice do not lack steroids in physiological conditions. Furthermore, steroid pretreatment suppresses both innate and adaptive immunity, leading to an immunocompromised status before CLP (2) and completely eliminates SR-BI expression in adrenal glands, leading to a lack of endogenous steroid production in SR-BI 1/1 mice during CLP (3). We found that SR-BI protects against sepsis regardless of the presence of steroids (Fig. 1B) or antibiotics (Fig. 1C) . The increased survival of SR-BI 2/2 mice observed by the authors is likely caused by the survival advantage of the mixed B6/129 background of the mice versus B6N controls and by altered immunity due to steroid pretreatment. 
